Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Progenitor (PGEN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (30)	2/24/1998 12:59:00 PM
From: Czechsinthemail	Respond to of 106

Rick, Thanks for the info on del-1 and your article, which I'm reposting for the benefit of others who would like more information on angiogenesis: investor.msn.com It sounds like PGEN's del-1 may be a very promising bet for a collaboration. The Lehman analyst said he expects an announcement on that collaboration sometime in 1H98. Here is a bit more from their news announcement on Del-1 from H. Ralph Snodgrass, Ph.D. PGEN's VP Research and Chief Scientific Officer: "The specificity of del-1 gene expression, as revealed in these functional studies, makes it a promising target for cancer therapy. The protein's specific binding with [lambda-V-beta-3] integrin makes it an attractive lead for small-molecule or peptide drugs to modulate blood vessel formation in conditions such as ischemia and restenosis folowing angioplasty." Baird